Rapid Auto-Injector Delivery of TXA for Critically Wounded Airmen
Award amount
$49,434Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Defense
- Branch
- Air Force
- Recipient company
- RX BANDZ, INC.
- Proposal award date
- 2021-04-14
- Contract end date
- 2021-07-19
- UEI
- DXRED7S6FVE9
- Solicitation number
- X21.1
- Topic code
- AF211-CSO1
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Shelf-life Extension for Emergency Medication
- Continue, Expand, and Refine Research and Development of a Hydromorphone Autoinjector
- Stop The Bleed - Save the Warfighter! : Intramuscular Auto-Injector Delivery of Tranexamic Acid (TXA) on the Battlefield
- Extended Utilization of Lifesaving Medications via Autoinjector
- Auto Injector Administration of Ketamine for Critically Injured Airmen
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Training the Ethical Employment of Lethal Autonomous Weapons (TEELAWS)
- Braided Ultra-High Temperature (UHT) Ceramic Matrix Composites (CMC) Scramjet Isolator Development
- SBIR Sequential Phase II (TACFI) Traditional Contract - Athenium Analytics Always Ahead
- Advanced Fielding and Deployment Dashboard Platform
- Starfish Space STRATFI
Research funding history
12 SBIR/STTR records share this UEI (2020–2023). Reported award amounts total $6,990,569. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Defense